A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acute decompensated heart failure. Evaluating Treatment with Nesiritide in Acute Decompensated Heart Failure (ETNA). - ETNA

GlaxoSmithKline Research & Development Limited0 个研究点目标入组 1,900 人开始时间: 2005年3月17日最近更新: 2012年10月9日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: GlaxoSmithKline Research & Development Limited
入组人数: 1,900

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•A subject will be considered eligible for inclusion in this study only if all of the
•following criteria apply:
•1. Male or female, at least 18 years of age and who has been hospitalised for the management of a primary diagnosis of adHF. Note for the small number of female subjects of childbearing potential who may enter the study an effective method of contraception must be used for the duration of the study (up to Day 30)
•2. The underlying primary aetiology of adHF and the presenting symptoms should be cardiac disease, rather than pulmonary disease (e.g. not cor pulmonale, nor pneumonia in addition to chronic HF)
•3. In relation to the acute episode, subjects must have at least one sign of heart failure as detailed below:
•tachypnoea (> 20 breaths/minute)
•increased jugular venous pressure (JVP), or 3rd/4th heart sound, or recent clinically significant weight gain indicative of oedema, or hepatic congestion.
•crackles/rales or pulmonary effusion evident on chest auscultation/ examination.
•4. In relation to the acute episode, subjects must have at least one piece of investigational evidence consistent with heart failure as detailed below:
•a chest X-ray upon admission with evidence of pulmonary congestion
•Left ventricular systolic ejection fraction performed within the past 12 months - Left ventricular ejection fraction should be =45% or the equivalent rating of at least moderately impaired left ventricular systolic function.
•5. Subjects must still have dyspnoea at rest or on minimal exertion (e.g. on sitting up) at the time of randomisation
•6. Subjects must have received at least one but not more than two doses of IV bolus diuretic within 24 hours prior to randomisation AND/OR, have been receiving a continuous infusion of IV diuretics for at least 2 hours immediately prior to randomisation at a constant dose. Bolus IV diuretic is not permitted within 1 hour prior to randomisation. The subject must be randomised within 24 hours of the initiation of IV treatment for HF.
•7. Chronicity of HF must be substantiated by: 1) documented clinical history of chronic HF and 2) investigational evidence of left ventricular systolic dysfunction (e.g. by echocardiography, ventriculography or nuclear cardiography) within the last 12 months. A current assessment (e.g. echocardiographic) can be performed if this information is not available from the medical history at the time of screening. NB: Left ventricular ejection fraction should be =45% or the equivalent rating of at least moderately impaired left ventricular systolic function
•8. The subject or legal representative must fully understand and sign the written informed consent prior to initiation of protocol-specified procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•A subject will not be eligible for inclusion in this study if any of the following criteria apply:
•1. Initiation of IV treatment for HF > 24 hours prior to randomisation
•2. Hospitalised for =48 hours prior to randomisation
•3. Baseline SBP
•a. Subjects who have not received or are not receiving either IV vasodilators (e.g. nitrates) or inotropes prior to randomisation are excluded if SBP = 100mmHg.
•b. Subjects who have received or are receiving either IV vasodilators (e.g. nitrates) or inotropes prior to randomisation are excluded if SBP < 120mmHg
•4. a. Subjects receiving continuous iv diuretics, iv vasodilators, or iv inotropes prior to randomisation whose dose has not remained stable for 2 hours prior to randomisation.
•b. Subjects receiving iv vasodilators, or iv inotropes whose SBP is unstable (e.g. progressively falling) or has fallen below 120mmHg within 2 hours prior to randomisation.
•5. Known or suspected acute coronary syndrome (ST-elevation or non-ST elevation myocardial infarction (MI) or unstable angina pectoris) within the past 2 weeks.
•6. Cardiogenic shock, evidence of uncorrected volume or sodium depletion (e.g. excessive diuresis or clinical signs of dehydration) or other clinical condition that would contraindicate the administration of IV vasoactive agents
•7. Evidence of malignant hypertension or severe persistent uncontrolled hypertension (blood pressure >190/115 mmHg).
•8. History of unexplained syncope
•9. Requiring mechanical ventilation, or mechanical circulatory support (e.g. intraaortic balloon pump, left ventricular assist devices) (subjects receiving CPAP prior to randomisation may be recruited), or likely to require dialysis or other renal replacement therapy post randomisation, or likely to undergo percutaneaous coronary intervention (PCI) or emergency surgery during admission.
•10. Subjects who have been resuscitated or received defibrillation during the admission prior to randomisation.
•11. Known allergic reaction to nesiritide or other IV therapy that may be critical to successful management of adHF (e.g. nitrate, inotropes, diuretics)
•12. The following co-morbidities: cardiac valvular stenosis, restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, pericardial tamponade or any condition likely to cause intolerance to vasodilators, severe pulmonary disease, concurrent pneumonia,
•13. adHF associated with: underlying congenital heart disease, thyrotoxicosis (or other conditions associated with high output cardiac failure), active myocarditis; or with uncontrolled haemodynamically relevant atrial fibrillation/flutter; or with ventricular rhythm disturbances or secondary to clinical evidence of digoxin toxicity or any other drug-related toxicity.
•14. Subjects with other significant, non-cardiac, co-morbidities (e.g. cancer) who are not anticipated to survive the 6 month follow-up
•15. Subjects whose condition requires long term IV vasoactive support (e.g. heart transplant candidate) or subjects whose acute cardiovascular condition is unlikely to be sufficiently improved to enable the subject to be discharged following study therapy
•16. Subjects who have undergone a heart transplant or who are waiting to undergo transplant surgery
•17. Subjects who have undergone coronary artery bypass graft (CABG) surgery or other cardiac/ major non-cardiac surgery within the past 30 days
•18. Therapy with another investigational drug within 5 half lives prior to the time of study entry which had not been pre-ap

研究者

发起方

GlaxoSmithKline Research & Development Limited

相似试验

进行中（未招募）

不适用

A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared to Daivobet® and vehicle in the treatment of adult patients with chronic stable plaque psoriasisChronic stable plaque psoriasis.MedDRA version: 17.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858

EUCTR2013-002861-20-PLek Pharmaceuticals d.d.411

进行中（未招募）

不适用

A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acute decompensated heart failure. Evaluating Treatment with Nesiritide in Acute Decompensated Heart Failure (ETNA). - ETNAAcute decompensated heart failure (adHF)MedDRA version: 7.1Level: LLTClassification code 10000803

EUCTR2004-005213-11-ISJanssen-Cilag International NV1,900

进行中（未招募）

不适用

EUCTR2004-005213-11-LTGlaxoSmithKline Research & Development Limited1,900

进行中（未招募）

不适用

EUCTR2004-005213-11-FIJanssen-Cilag International NV1,900

进行中（未招募）

1 期

EUCTR2004-005213-11-IEGlaxoSmithKline Research & Development Limited